The influenza virus neuraminidase (NA) inhibitors zanamivir and oseltamivir were introduced into clinical practice in various parts of the world between 1999 and 2002. In order to monitor the potential development of resistance, the Neuraminidase Inhibitor Susceptibility Network was established to coordinate testing of clinical isolates collected through the World Health Organization influenza ...

conclusions although the patients carrying m204i mutation were more likely to show lack of responses to lam therapy, lam replacing by other nucleoside/tide analogs plus hbig maybe still effective in decreasing hepatitis b recurrence after liver transplantation. however, it is suggested that drug resistance test should be considered by clinicians during therapeutic management to avoid the follow...

BACKGROUND Among Influenza neuraminidase inhibitors (NAIs), oseltamivir corresponds to the most widely used agent to treat influenza disease. However since 2001, several cases of resistance to NAIs have been reported for circulating seasonal A(H1N1) Influenza viruses. A direct resistance mechanism may be invoked, involving critical mutations in the viral NA gene that prevent the drug binding to...

Subtype-specific neuraminidase (NA) mutations conferring resistance to NA inhibitors (NAIs) have been reported during in vitro passages and in clinic. In this study, we evaluated the impact of various NA mutations (E119A/G/V, H274Y, R292K and N294S) on the susceptibility profiles to different NAIs (oseltamivir, zanamivir and peramivir) using recombinant NA proteins of influenza A/WSN/33 (H1N1) ...

antimalarial drugs with the 4-aminoquinoline scaffold such as the important drugs, chloroquine (cq) and amodiaquine (aq), have been used to prevent and treat malaria for many years. the importance of these drugs is related to their simple usage, high efficacy, affordability, and cost-effectiveness of their synthesis. in recent years, with the spread of parasite resistance to cq and cross-resist...

nowadays the most difficult problem in treatment of bacterial infections is the appearance of resistant bacteria to the antimicrobial agents so that the attention is being drawn to other potential targets. in view of the positive findings of phage therapy, many advantages have been mentioned which utilizes phage therapy over chemotherapy and it seems to be a promising agent to replace the antib...

Neuraminidase (NA) is a surface glycoprotein produced by the influenza virus. Specific NA mutations that confer resistance to anti-viral drugs have been reported. The aim of this study was to demonstrate quick preparation of the mutated NAs using the yeast surface display and its applicability for screening inhibitors. Plasmids encoding the head domain of wild-type and drug-resistant NAs were c...

Currently approved neuraminidase inhibitors (NAI) for the treatment of influenza A virus infections are prone to induce viral drug resistance development due to the rapid evolutionary dynamics of the neuraminidase (NA) and hemagglutinin (HA) proteins. Both HA and NA proteins are subject to antigenic drift and the epistatic interactions within and between these proteins can lead to genetic diver...